Abstracts Archive - Page 2590 of 2607 - ACR Meeting Abstracts

Abstract Number: 195 • 2012 ACR/ARHP Annual Meeting
Inflammatory Arthritis in Patients with Myelodysplastic Syndrome: French Multicenter Retrospective Study
Arsene Mekinian¹, Olivier Decaux², Geraldine Falgarone³, Thorsten Braun Sr.⁴, Eric Toussirot⁵, Loic Raffray⁶, Bruno Gombert⁷, Bruno de Wazieres⁸, Anne Laure Buchdaul⁹, Jean-Marc Ziza¹⁰, David Launay¹¹, Guillaume Denis¹², Serge Madaule¹³, Pierre Fenaux¹⁴ and Olivier Fain¹⁵, ¹Internal Medicine, Jean Verdier Hospital, Bondy, FL, France, ²Department of Internal Medicine, Rennes University Hospital, Rennes, France, ³Rheumatology, Hopital avicenne, Paris, France, ⁴Hematology, Avicenne hospital, Bobigny, France, ⁵Université de Franche Comté , CHRU, CIC Biotherapy 506 and Rheumatology and EA 4266 Pathogens and Inflammation, Besançon, France, ⁶Internal Medicine, CHU de Bordeaux, Bordeaux, France, ⁷Internal Medicine, La Rochelle hospital, La Rochelle, France, ⁸Internal Medecine, CHU de Nimes, Nimes, France, ⁹Internal Medicine, Douai hospital, Douai, France, ¹⁰Rheumatology, Croix Saint Simon Hospital, Paris, France, ¹¹Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹²Internal Medicine, Rochefoucault hospital, Rochefoucault, France, ¹³Rheuamtology, Albi hospital, Albi, France, ¹⁴Hematology, Avicenne Hospital, France, ¹⁵Internal Medicine, Jean Verdier Hospital, Bondy, France
Inflammatory arthritis in patients with myelodysplastic syndrome: French multicenter retrospective study.For the Société Nationale Française de Médecine Interne (SNFMI), the CRI (Club Rhumatismes Inflammation) and…
Abstract Number: 196 • 2012 ACR/ARHP Annual Meeting
Sarcoidosis in Northern New England. Clinical Characteristics and Predictive Factors for More Aggressive Therapy
Alireza Meysami¹, Kevin F. Spratt² and Christopher M. Burns³, ¹Rheumatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Department of Orthopaedic Surgery, Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Dartmouth Medical School, Lebanon, NH
· Background/Purpose: Sarcoidosis is characterized by a variable clinical presentation. DMARDs and biologics have been used for resistant and/or organ-threatening disease. We analyzed the cases…
Abstract Number: 197 • 2012 ACR/ARHP Annual Meeting
Collapsing Glomerulopathy in Collagen Vascular-Like Disease
Rawad Nasr¹, Christine Johns² and Elie Gertner³, ¹Rheumatology - Internal Medicine, University of Minnesota, Minneapolis, MN, ²Section of Nephrology, Regions Hospital, St Paul, MN, ³Section of Rheumatology, Regions Hospital and University of Minnesota Medical School, St. Paul, MN
Background/Purpose: Background: Collapsing Glomerulopathy (CG) is an uncommon podocytopathy with distinct clinical and pathological characteristics. It is usually associated with HIV disease or parvovirus B19…
Abstract Number: 198 • 2012 ACR/ARHP Annual Meeting
Diagnostic Predictors and Clinical Outcomes in Patients Presenting Solely with Lymphadenopathy
Huifang Lu, Xerxes Pundole and Khanh Vu, General Internal Medicine, UT MD Anderson Cancer Center, Houston, TX
Background/Purpose: Patients presenting solely with radiologic evidence of lymphadenopathy (LAD) to tertiary cancer centers are often diagnosed with malignancy or autoimmune diseases such as sarcoidosis.…
Abstract Number: 199 • 2012 ACR/ARHP Annual Meeting
Joint, Hand and Feet Swelling As a Presenting Symptom of Hereditary Angioedema
Maria J. Gutierrez¹ and Timothy J. Craig², ¹Department of Pediatrics, Division of Pediatric Rheumatology. Department of Medicine, Section of Allergy and Immunology, Penn State College of Medicine Milton S. Hershey Medical Center, Hershey, PA, ²Department of Medicine. Division of Pulmonary, Allergy and Critical Care Medicine, Penn State College of Medicine Milton S. Hershey Medical Cente, Hershey, PA
Background/Purpose: Hereditary Angioedema (HAE) is a rare disorder caused by deficiency or impaired function of C1 esterase inhibitor. Early and accurate diagnosis of HAE is…
Abstract Number: 200 • 2012 ACR/ARHP Annual Meeting
Rheumatic Manifestations and Connective Tissue Diseases in Autoimmune Hepatitis of the Child and the Adult
Federico Zazzetti¹, Nora C. Fernandez², Javier Benavidez², Luis A. Colombato³, Graciela R. Rodriguez⁴, Graciela Nardi⁵, Carolina Bru Morón⁶, Oscar L. Rillo⁷, Nelo A. Quadrini⁸, Stella M. Garay⁹, Mariana Fabi⁹, Teresita Gonzalez¹⁰ and Juan C. Barreira¹¹, ¹Rheumatology, Buenos Aires Hospital Britanico, Buenos Aires, Argentina, ²Hepatology, Buenos Aires British Hospital, Buenos Aires, Argentina, ³Gastroenterology, Buenos Aires British Hospital, Buenos Aires, Argentina, ⁴Rheumatology, Hospital Dr. Ignacio Pirovano, Buenos Aires, Argentina, ⁵Gastroenterology, Hospital Dr. Ignacio Pirovano, Buenos Aires, Argentina, ⁶Rheumatology, Hospital Dr. Enrique Tornú, Buenos Aires, Argentina, ⁷Rheumatology, Hospital General de Agudos "Dr. E. Tornú", Buenos Aires, Argentina, ⁸Gastroenterology, Hospital Dr. Enrique Tornú, Buenos Aires, Argentina, ⁹Rheumatology, Hospital IAEP Sor María Ludovica, La Plata, Argentina, ¹⁰Hepatology, Hospital IAEP Sor María Ludovica, La Plata, Argentina, ¹¹Rheumatology, Buenos Aires British Hospital, Buenos Aires, Argentina
Background/Purpose: Autoimmune hepatitis (AIH) is a progressive fibrosing inflammatory disease of the liver of unknown etiology, leading to cirrhosis. Its course is usually fluctuating and…
Abstract Number: 201 • 2012 ACR/ARHP Annual Meeting
High Rate of Autoimmune Manifestations During Idiopathic CD4 Lymphocytopenia
Alexis Régent¹, Brigitte Autran², Guislaine Carcelain², Benjamin Terrier³, Alain Krivitzky⁴, Eric Oksenhendler⁵, Nathalie Costedoat-Chalumeau⁶, Pascale Hubert², Olivier Lortholary⁷, Nicolas Dupin⁸, Patrice Debré², Loic Guillevin⁹ and Luc Mouthon¹, ¹Internal Medicine, Hopital Cochin, Paris, France, ²INSERM, UMR945, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire d'Immunologie Cellulaire Et Tissulaire, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁴Département de médecine interne, Hôpital Avicenne, AP-HP, Bobigny, France, ⁵Département d'Immunologie Clinique, Hôpital Saint-Louis, AP-HP, Paris, France, ⁶Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁷Service de maladies infectieuses, Hôpital Necker-Enfants malades, AP-HP, Paris, France, ⁸Service de Dermatologie, Hôpital Cochin, AP-HP, Paris, France, ⁹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: When first described by the Center for Disease Control, idiopathic CD4 lymphocytopenia (ICL) was characterized by opportunistic infections in patients with a CD4 count≤300/mm3…
Abstract Number: 202 • 2012 ACR/ARHP Annual Meeting
Diseases Associated with Markedly Elevated Ferritin Levels
Reshma Marri¹, Payal J. Patel², Amita Thakkar³, Rochella A. Ostrowski⁴, Eric McBride¹ and Rodney Tehrani⁵, ¹Rheumatology, Loyola Univ Medical Ctr, Maywood, IL, ²Internal Medicine, Loyola Univ Medical Ctr, Maywood, IL, ³Loyola Univ Medical Ctr, Maywood, IL, ⁴Rheumatology, Loyola University Medical Center, Maywood, IL, ⁵Allergy, Immunology, and Rheumatology, Loyola University Medical Center, Maywood, IL
Background/Purpose: Adult onset Still’s disease (AOSD) is a rare form of inflammatory arthritis with inflammatory systemic disease of unknown etiology. It is a diagnosis of…
Abstract Number: 203 • 2012 ACR/ARHP Annual Meeting
Clinical Course Factors Associated with Outcome of Monoarthritis : A Retrospective Study of 173 Cases
Hyemin Jeong¹, Eun-Jung Park¹, Jiwon Hwang¹, Ji Young Chai², Joong Kyong Ahn³, Eun-Mi Koh⁴ and Hoon-Suk Cha¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Division of Rheumatology, Jesang Hospital, Seongnam-si Gyeonggi-do, South Korea, ³Department of Medicine, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Seoul, South Korea
Background/Purpose: To evaluate the clinical features and outcomes in patients with monoarthritis and to investigate predictive factors associated with the clinical course in terms of…
Abstract Number: 204 • 2012 ACR/ARHP Annual Meeting
Characterization of Joint Disease in Mucopolysaccharidosis Type I Mice and the Effects of Enzyme Replacement Therapy
Patricia Oliveira¹, Guilherme Baldo², Fabiana Mayer², Barbara Martinelli², Luise Meurer³, Roberto Giugliani², Ursula Matte² and Ricardo M. Xavier⁴, ¹Rheumatology, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, ²Genetics, Hospital de Clinicas de Porto Alegre, ³Pathology, Hospital de Clinicas de Porto Alegre, ⁴Rheumatology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Background/Purpose: Mucopolysaccharidosis type I (MPS I) is a lysosomal disorder caused by deficiency of alpha-L-iduronidase, which leads to storage of glycosaminoglycans. Patients with MPS I…
Abstract Number: 205 • 2012 ACR/ARHP Annual Meeting
Idiopathic Inflammatory Myositis Is Associated with an Increased Incidence of Systemic Sclerosis
Shreyas H. Chaudhary¹, Susanna Proudman² and Vidya S. Limaye³, ¹Medical Student University of Adelaide, Adelaide, Australia, ²Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ³Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: Systemic sclerosis (SSc) and idiopathic inflammatory myositis (IIM) are two systemic autoimmune connective tissue diseases with predominant effects on skin and muscle respectively .…
Abstract Number: 206 • 2012 ACR/ARHP Annual Meeting
Clinical, Laboratory, and Cellular Responses in the Rituximab in Myositis Trial in Patients Enrolled At the National Institutes of Health
Lisa G. Rider¹, Adrienne L. Yip², Iren Horkayne-Szakaly³, Rita Volochayev², Joseph A. Shrader⁴, Maria L. Turner⁵, Heidi H. Kong⁵, Minal S. Jain⁴, Anna V. Jansen¹, Chester V. Oddis⁶, Thomas A. Fleisher⁷ and Frederick W. Miller¹, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ²National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³Joint Pathology Center, Silver Spring, MD, ⁴Rehabilitation Medicine, Rehab Medicine, NIH Clinical Center, Bethesda, MD, ⁵Dermatology Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, ⁶Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Laboratory Medicine, Laboratory Medicine, NIH Clinical Center, Bethesda, MD
Background/Purpose: To assess changes in myositis core set measures, clinical and laboratory data, and paired muscle biopsies from NIH patients enrolled in the Rituximab in…
Abstract Number: 167 • 2012 ACR/ARHP Annual Meeting
Serum Uric Acid Control and Risk of Flare According to Different Cut-Offs in Patients with Gout: Longitudinal Analysis From the King Study of the Italian Society for Rheumatology
Maria Manara¹, Carlo Alberto Scirè¹, Marco A. Cimmino², Marcello Govoni³, Fausto Salaffi⁴, Greta Carrara¹, Carlomaurizio Montecucco⁵, Marco Matucci-Cerinic⁶, Giovanni Minisola⁷ and Kick-off of the Italina Network for Gout (KING) Study Group⁸, ¹Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, ²Rheumatology - Department of Internal Medicine - University of Genoa, Genova, Italy, ³Clinical and Experimental Medicine, Section of Rheumatology, University of Ferrara, Ferrara, Italy, ⁴Rheumatology Unit - Polytechnic University of the Marche, Jesi, Italy, ⁵Division of Rheumatology - University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ⁶Department of Biomedicine & Division of Rheumatology AOUC - University of Florence, Florence, Italy, ⁷Rheumatology Unit - San Camillo Forlanini Hospital, Rome, Italy, ⁸Italian Society for Rheumatology, SIR, Italy
Background/Purpose: the therapeutic goal of the management of gout is to promote crystal dissolution and prevent crystal formation. For this reason national and international guidelines…
Abstract Number: 168 • 2012 ACR/ARHP Annual Meeting
Allopurinol Use Is Associated with a Decreased Risk of Myocardial Infarction
Lamiae Grimaldi-Bensouda¹, Annick Alpérovitch², Elodie Aubrun¹, Nicolas Danchin³, Michel Rossignol⁴, Lucien Abenhaim⁵, Pascal Richette⁶ and PGRx MI Group⁷, ¹LA-SER, Paris, France, ²Inserm U708-Neuroepidemiology, La Pitié-Salpêtrière Hospital, Paris, France, ³Coronary disease unit, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris and Paris-Descartes University, Paris, France, ⁴LA-SER, Centre for Risk Research, Montreal, Canada, ⁵LA-SER Europe Ltd, London, United Kingdom, ⁶Lariboisière Hospital, Paris, France, ⁷Paris, France
Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and the oxidative stress in the vasculature, which are known cardiovascular risk factors. However, the effects…
Abstract Number: 169 • 2012 ACR/ARHP Annual Meeting
Post-Marketing Safety Surveillance Data Reveals Patterns of Use for Pegloticase in Refractory Chronic Gout
Kenneth M. Bahrt¹, Anthony E. Yeo², Tina L. Howson³ and Faith D. Ottery¹, ¹Medical Affairs, Savient Pharmaceuticals, Inc., East Brunswick, NJ, ²Savient Pharmaceuticals, Inc., East Brunswick, NJ, ³Savient Pharmaceuticals, Inc., Bridgewater, NJ
Background/Purpose: Pegloticase is a recombinant modified mammalian uricase conjugated to mPEG which was approved in the US in 2010 for treating hyperuricemia in patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].